SCYNEXIS Names Sanjay Subramanian Chief Financial Officer

Bitget2026/11/05 13:20

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

SCYNEXIS appointed Sanjay S. Subramanian CFO effective September 9, 2026; previously Inozyme Pharma's CFO and head of business development.
Subramanian succeeds Ivor Macleod, who retired September 9 and remained through October 9 to support the transition.
Todd Minga, a nephrologist with over two decades of kidney-disease research experience, became senior vice president, research and development, effective September 14.
Steven K. Burke joined the board effective September 18, serving on the Nominating and Corporate Governance Committee.
Burke previously served as Akebia Therapeutics' senior vice president, chief research and development officer and chief medical officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCYNEXIS Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050820PRIMZONEFULLFEED9870822) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

SCYNEXIS Names Sanjay Subramanian Chief Financial Officer

You may also like

Crypto prices